[Effect of immunochemotherapy on the cases of advanced gastric cancer stage III].
This study was conducted in patients with stage III gastric cancer who were admitted and gastrectomized in our Department of Surgery during July 1971 to March 1980. The control group consisted of 32 patients who were treated with mitomycin C and FT -207 during the first half of the period and the levamisole (LMS) group of 32 patients who were treated with the same regimen plus LMS during the latter half of the period. No significant statistical difference in their back ground factors was found. The LMS group was treated with 150 mg/day of LMS for 3 consecutive days every other week starting 3 days before operation. The follow-up study up to 30 postoperative months indicated an enhancing effect of LMS on the survival rate in patients with gastric cancer stage III undergoing curative resection. LMS proved to be effective on inhibition of the tumor growth when the tumor sizes ranged 4.0 to 7.9 cm, and the metastases were limited within the regional lymph node.
D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000008:administration & dosage; D005743:Gastrectomy; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009367:Neoplasm Staging; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*
D008937:Mitomycins; D007978:Levamisole; D016685:Mitomycin; D005472:Fluorouracil